Reeder-Hayes KE et al. - Chemotherapy (doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab [ACTH] or docetaxel, carboplatin, and trastuzumab [TCH]). in combination with trastuzumab is currently the standard of care for HER2+ breast cancer; however, the efficacy and safety of these regimens has not been established for older patients. In the current study, ACTH was not associated with a higher rate of serious adverse events or hospitalizations compared to TCH. Moreover, there was no difference in 5-year survival outcomes for ACTH compared with TCH.